DB15856InvestigationalVaccines
AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike... The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA vaccine product.
- Code names
- AG0301-COVID19
What you can answer from here — as of September 18, 2020
Which companies are running trials of AG0301-COVID19, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account